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Body mass index (BMI) is correlated with circulating metabolites but few studies discuss other 
adiposity measures and little is known about metabolomic correlates of body mass index from early 
life. We investigated associations between different adiposity measures, BMI from childhood through 
adulthood, and metabolites quantified from serum using 1H NMR spectroscopy in 900 British men 
and women aged 60-64. We assessed BMI, waist-to-hip ratio (WHR), and android-to-gynoid fat ratio 
(AGR) and BMI from childhood through adulthood. Linear regression with Bonferroni adjustment 
was performed to assess adiposity and metabolites. Of 233 metabolites, 168, 126, and 133 were 
associated with BMI, WHR and AGR at age 60-64, respectively. Associations were strongest for high 
density lipoprotein (HDL), particularly HDL particle size, e.g. there was 0.08 SD decrease in HDL 
diameter (95% CI: 0.07-0.10) with each unit increase in BMI. BMI-adjusted AGR or WHR were 
associated with 31 metabolites where there was no metabolome-wide association with BMI. We 
identified inverse associations between BMI at age 7 and glucose or glycoprotein at age 60-64 and 
relative large LDL cholesterol ester with post-adolescent BMI gains. In summary, we identified 
metabolomic correlates of central adiposity and earlier life BMI. These findings support opportunities 
to leverage metabolomics in early prevention of cardiovascular risk attributable to body fatness. 
  

























Obesity predisposes to CVD (4) but it is unclear which aetiological pathways are affected by obesity. 
Recently, high-throughput analysis of biological samples has allowed quantification of small-
molecule metabolites (5) downstream from genome or gene, mRNA, and protein (6), reflecting an 
integrated metabolic profile (7–9).  This metabolome-wide approach has shown aberrations in 
metabolic profile to be predictive of CVD (10, 11). A Mendelian randomization study suggested that 
higher BMI is associated with altered levels of some CVD-related metabolites including lipoprotein 
lipid and cholesterol contents, saturated fatty acids, branched-chain (BCAA) and aromatic amino 
acids, and inflammatory metabolites (14). However, adults with similar BMI may have different fat 
distributions (15). It is not clear whether central adiposity is associated with metabolite levels 
independent of BMI in late adulthood when central adiposity becomes more common. Further, there 
is indication that changes in BMI over up to 7 years are associated with metabolic profile (14, 16). 
However, it is unclear which metabolites are affected by changes in BMI across the life course, which 
is important given the effect of childhood BMI changes on cardiovascular function in adulthood (17, 
18). Therefore, we assessed the similarities and differences between associations of BMI and central 
adiposity measures, as well as body size across the life course, with metabolic profile at age 60-64 in 
the MRC NSHD birth cohort.  
 
Materials and methods 
Study population 
The Medical Research Council (MRC) National Survey of Health and Development (NSHD) has been 
described in details (19). From this population, we included individuals with measurements of at least 
one circulating metabolite, and information on BMI, waist and hip circumferences at age 60-64 
(N=900). A flowchart depicting selection of final study population is shown as Supplemental Figure 
S1. Ethical approval was obtained from the Greater Manchester Local Research Ethics Committee 
and the Scotland Research Ethics Committee. Written informed consent was obtained from the study 
member for each component of each data collection. 
 
 













Targeted metabolomics analysis was performed on serum samples collected at age 60-64. Metabolites 
were quantified by an automated NMR metabolomics platform (Bruker AVANCE III 500 MHz and 
Bruker AVANCE III HD 600 MHz spectrometers) which have been widely used in published studies 
(21). A total of 233 metabolite concentrations and derived measures were obtained (Supplemental 
Table S1, Supplementary Information). Of 233 metabolites, 159 (72%) were measured in all included 
participants. The remaining metabolites had <1.5% missing values. Metabolite measures that deviated 
from normality were log-transformed (Supplemental Table S1, Supplementary Information) and all 
measures were standardised. 
 
Assessment of adiposity  
At ages 60-64, weight (kg), height (m), waist and hip circumference (cm) were measured using 
standardised protocols by trained nurses (19). Weight and height were also measured at ages 7, 15, 36, 
43, and 53 and BMI (kg/m2) was calculated. Measures of body composition at age 60-64 were 
obtained in the supine position using a QDR4500 Discovery DXA scanner (Hologic Inc, Bedford, 
MA, USA); and reviewed using a single operator using APEX 3.1 software (Hologic Inc., Bedford, 
MA, USA) (15). Measures of android and gynoid fat mass were obtained and the ratio between the 
two (android-to-gynoid ratio) was calculated (higher values indicating greater fat distribution in the 
abdomen than hips).  
 
Other covariates 
Systemic metabolites have been reported to be altered with lipid medications (22), diabetes (23), and 
other chronic diseases (24). Self-reported information on use of statin, diabetes diagnosis and 
unintentional weight loss was therefore collected. Unintentional weight loss, which may represent 




Association between current adiposity and systemic metabolites  












Ordinary least square (OLS) regression was used with the adiposity measure (BMI, WHR, or AGR) as 
the predictor for each metabolite, adjusting for sex, age and clinic. Models for WHR and AGR were 
further adjusted for BMI. A sensitivity analysis was performed by restricting the models to those 
without statin use (N=698), diabetes (N=849), or unintentional weight loss (N=856). To address 
potential correlation between metabolites (9), we repeated the analysis for each adiposity measure 
using a multivariate approach, orthogonal partial least square (OPLS) (26). Metabolites with a 
variable importance in projection (VIP)≥1 were deemed strongly correlated with adiposity (27).  
 
Association between prior BMI and systemic metabolites  
We then investigated how prior BMI was associated with levels of metabolites. OLS regression 
models were employed to assess BMI in childhood (age 7; N=766), adolescence (age 15; N=722), and 
adulthood (age 36, 43 and 53; N=836, 855, and 859, respectively) and metabolite levels at age 60-64. 
Significant associations for prior BMI were further adjusted for BMI at age 60-64 in order to assess 
whether prior BMI was associated with metabolite level over and above current BMI (28, 29). Since 
the numbers of participants who had data on prior BMI were smaller than the maximum sample, we 
performed a sensitivity analysis assessing associations between BMI at all ages and metabolites in 
participants who had complete data on all BMI measures (N=569).   
 
Association between BMI gains and systemic metabolites  
In the main sample, we assessed whether there were sensitive periods in life during which BMI gains 
are associated with metabolites in late adulthood. This was conducted for age 7 to 15, 15 to 36, 36 to 
43, 43 to 53, and 53 to 60-64 by regressing each BMI measure on the BMI measured earlier for each 
sex. Higher residuals represented greater BMI gains than expected (30). Each set of residuals was 
standardised and used as predictors of metabolites to address whether there are periods when gain in 
BMI was associated with later life metabolites. 
 
For each model, we used a Bonferroni-adjusted significance threshold for 233 tests (p-value<0.0002). 
All analyses were conducted in R statistical software version 3.3.2 (R Foundation for Statistical 
Computing, Vienna, Austria).  














Characteristics of study members are shown in Supplemental Table S2. The majority had non-manual 
occupations and were overweight at age 60-64. Pairwise correlations between metabolites are 
presented as Supplemental Figure S2.  
 
Association between current adiposity and systemic metabolites  
In OLS (N=900), 168 metabolites were associated with BMI (Figure 1), 126 with WHR (Figure 2), 
and 133 with AGR (Supplemental Figure S3). After adjusting for BMI, 63 metabolites remained 
associated with WHR and 106 with AGR (Supplemental Figure S4-5). Associations were strongest 
for high density lipoprotein (HDL) particle diameter (HDL D) and concentration of very large HDL 
phospholipids (XL HDL PL) (Table 1). Sensitivity analyses excluding participants with statin use, 
diabetes or unintentional weight loss yielded similar results (data not shown). We identified 25 
metabolites in men and 5 in women which were associated with WHR or AGR when adjusted for 
BMI, but they were not associated with BMI in the main sex-stratified analysis (Table 2).  
 
In OPLS, six predictors or principal components explained the association between metabolites and 
each measure of adiposity. Taking such clustering into account, a total of 99 metabolites were shown 
to be associated with BMI (VIP≥1), 87 with WHR and 90 with AGR. Common metabolites identified 
by both the hypothesis-testing approach and OPLS are indicated in Figure 1-2, Supplemental Figure 
S3 for BMI, WHR and AGR, respectively. Agreement between the two methods was high for 
associations of BMI, WHR and AGR with metabolite markers of very large and large HDL, large and 
medium VLDL, lipoprotein particle size and BCAAs. HDL diameter was consistently among top ten 
metabolite correlates of BMI, WHR, and AGR in the OPLS analysis (Supplemental Table S3). 
 
Association between prior BMI and systemic metabolites 
Associations between prior adult BMI and metabolites showed similar albeit weaker trends to current 
BMI (Supplemental Figure S6; Table 2). More metabolites were associated with more recent BMI, 
with 125, 147 and 162 metabolite correlates seen for BMI at age 36, 43, and 53, respectively. Of 












these, only 3 remained associated with BMI at age 43 and 11 with BMI at age 53 when adjusted for 
BMI at age 60-64 (Supplementary Figure S6). No association was observed between BMI at age 7 or 
15 with systemic metabolites at age 60-64. However, upon adjustment with BMI at age 60-64, we 
found BMI at age 7 to be inversely related with 0.11 SD decrease in glucose (95% CI: -0.06 to -0.15) 
and 0.10 SD decrease in glycoprotein (-0.05 to -0.15).  
 
The sensitivity analysis in the subset of participants who had complete data of prior BMI showed 
similar results (data not shown); and after adjustment with current BMI, only one metabolite, small 
LDL phospholipids (S LDL PL) remained associated with previous BMI, i.e. BMI at age 43. 
 
Association between BMI gains and systemic metabolites 
BMI gains from adolescence through adulthood were consistently related to very large and large HDL 
metabolites (Figure 3). Apart from these, BMI gains at the latter ages were also associated with larger 
VLDL metabolites, and adolescent gains with relative contents of smaller VLDL and LDL 
metabolites, medium HDL, fatty acids, and aromatic amino acids (Figure 3). One metabolite, relative 
large LDL cholesterol ester (L LDL CE %), decreased with greater BMI gain between age 15 and 36 
but was not associated with change at other ages or BMI at age 60-64. Small HDL total lipids (S HDL 
L), was associated with BMI gains between age 43 and 53 but not with other periods or current BMI.  
 
Discussion 
We showed associations between current adiposity and systemic metabolites in late adulthood and 
BMI in earlier ages. Most consistent associations were observed for HDL metabolism. We identified 
25 metabolite measures independently associated with central adiposity but not BMI. When 
controlling for BMI at age 60-64, greater BMI at age 7 were correlated with lower glucose and 
glycoprotein at age 60-64. We also revealed lower relative large LDL cholesterol ester at age 60-64 
with greater adolescent-to-adulthood BMI gains. 
 
Our cross-sectional findings for BMI and metabolites in early old age corroborate prior findings 
linking body size and metabolites, including causal associations observed using a Mendelian 












randomisation study of young adults (31).  Similar to that study, we found associations between BMI 
and a number of metabolites including HDL metabolites, BCAAs, markers of glycolysis and 
inflammation. This may suggest that BMI influences metabolites in a similar manner throughout 
adulthood. Metabolite correlates of central adiposity also align with those identified in previous 
studies, such as lipoprotein concentration, HDL particle size, and BCAAs (32–35). We added to these 
findings by presenting data in late adulthood in which central obesity is common, including specific 
lipoprotein components, and identifying associations independent of BMI. Central adiposity may 
represent visceral rather than overall accumulation of fat (37). There were more metabolites 
specifically linked to central adiposity in men compared to women. This may support sexual 
dimorphism in regulation of fat depot and systemic metabolism (32, 36).  
 
A similar pattern to current BMI was observed with greater past BMI or its increments, which is in 
line with a previous study assessing metabolites linked to a 7 year weight change in adults aged 62-77 
(16). Although this may indicate BMI tracking, there were remaining associations between past BMI 
in adulthood and current metabolites after taking into account current BMI. Plausible mechanisms by 
which high BMI  in earlier adulthood  may affect metabolites in early old age may involve excess 
adiposity affecting systemic processes such as inflammation and oxidative stress (38) or predisposing 
to maladaptive lifestyles such as physical inactivity (39). Additionally, we identified specific 
metabolite correlates of BMI at age 7 after adjusting for BMI at age 60-64, and of BMI gains from 
adolescence to early adulthood which were different to late adulthood. The inverse associations of 
BMI at age 7 with glucose and glycoprotein, both of which are greater with higher BMI at age 60-64, 
may indicate that they were particularly responsive to greater gains in BMI between childhood and 
adulthood. These metabolites have been associated with adverse metabolic pathways including insulin 
resistance and advanced glycated end (AGE) products which are often activated in obesity (38, 40).  
 
Strengths and limitations 
The strength on this study lies in the longitudinal measurements of BMI from childhood through 
adulthood, and measurements of body fat distribution in early old age. A limitation of this study is the 
smaller number of those with information on prior BMI. However, findings comparing prior BMI 












were similar in a sensitivity analysis limited to those with complete lifelong BMI information. 
Metabolites were only measured on one occasion. Individuals who had higher BMI were at higher 
risk of cardiovascular disease and may have died or dropped out of the study prior to metabolite 
quantification at age 60-64, and this may result in underestimation of the observed associations. Our 
NMR platform only included absolute or relative quantification of metabolites. Future studies of 
adiposity could investigate other characteristics of metabolites such as aggregation susceptibility since 
LDL aggregation has been shown to be associated with CVD and is potentially modifiable by 
treatment (46).  
 
Conclusion 
We found metabolite correlates of current and past measures of BMI, which imply that metabolic 
profiling may be valuable for interventions aiming to mitigate the impacts of excess adiposity across 
adult life. The suggestion of alternative mechanisms for central adiposity and childhood BMI, which 
are independent of current BMI at age 60-64, indicates importance of future research on body 
composition and longitudinal measures of adiposity. 
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Table 1. Ten metabolites associated with each adiposity measure at highest precision. Positive (inverse) associations were highlighted in blue 
(red), respectively. Significant results with adjustment for multiple testing are indicated in white. For abbreviations see Supplemental Table S1. 
BMI WHR* AGR* 
Prior BMI Conditional BMI change Overweight 
onset 7 15 36 43 53 7 to 15 15 to 36 36 to 43 43 to 53 53 to 60-64 
L HDL FC L HDL FC % HDL D S HDL C ApoA1 L HDL FC % ApoA1 L HDL FC IDL TG % XL HDL PL ApoA1 HDL D L HDL PL % XL HDL FC 
HDL D LA % XL HDL PL SM IDL C % XL HDL PL HDL C HDL D IDL C % XL HDL FC HDL C L HDL FC Pyr XL HDL PL 
XL HDL PL Gp L LDL FC % FAw3 IDL TG % ApoA1 L HDL FC XL HDL PL L HDL PL % L HDL FC L HDL FC XL HDL PL L HDL FC % HDL D 
L HDL FC % L HDL PL % TG PG EstC M HDL C % HDL C L HDL FC % XL HDL FC FAw6 % L HDL FC % HDL2 C M VLDL CE % L HDL FC L HDL FC 
L HDL C FAw6 % XL HDL P S HDL CE XL HDL FC % XL HDL FC XL HDL FC XL HDL P S LDL TG % HDL D L HDL FC % M VLDL TG % PUFA % XL HDL L 
XL HDL P L HDL C % XL HDL L PUFA HDL2 C L HDL FC XL HDL PL XL HDL L L HDL FC % HDL C HDL D L VLDL TG XL VLDL TG XL HDL P 
XL HDL L XL HDL PL Ile Serum C Alb HDL2 C HDL2 C L HDL FC % XL HDL FC XL HDL L L HDL C TG PG L HDL C L HDL FC % 
XL HDL FC PUFA % L HDL FC S LDL PL HDL C HDL D HDL D L HDL P S HDL TG XL HDL P L HDL CE XL HDL P L VLDL FC XL HDL C 
L HDL CE Leu M VLDL TG ApoA1 L LDL TG % XL HDL L XL HDL L HDL C XL HDL C XS VLDL FC % L HDL L XL HDL L L HDL CE HDL C 
L HDL P HDL D VLDL TG S LDL C S LDL TG % XL HDL P XL HDL P ApoA1 HDL2 C L HDL C XL HDL FC L VLDL P XL VLDL P L HDL C 
*Adjusted for BMI












Table 2. BMI-adjusted associations between body fat distribution and metabolites without 
associations with BMI at Bonferroni-adjusted significance level. 
 
Metabolite Android-to-gynoid ratio Waist-to-hip ratio 
  N Estimate CI N Estimate CI 
 Men       
Medium VLDL cholesterol esters 368 1.30 0.70 to 1.90      
Medium VLDL free cholesterol (%) 368 1.24 0.73 to 1.76      
Small VLDL phospholipids 368 1.59 1.06 to 2.12 465 3.56 1.88 to 524 
Small VLDL total cholesterol 368 1.35 0.79 to 1.91 465 3.80 2.05 to 5.45 
Small VLDL cholesterol esters      465 3.61 1.81 to 5.40 
Small VLDL free cholesterol 368 1.66 1.13 to 2.19 465 3.67 1.97 to 5.36 
XS VLDL concentration      465 3.48 1.68 to 5.26 
XS VLDL cholesterol esters (%) 368 -1.25 -1.86 to -0.64      
Small LDL free cholesterol (%)      465 -3.86 -5.87 to -1.84 
IDL triglycerides      465 3.28 1.67 to 4.89 
Large LDL triglycerides      465 3.65 1.86 to 5.44 
Medium LDL triglycerides      465 3.43 1.78 to 5.09 
Small LDL triglycerides 368 1.24 0.63 to 1.84 465 4.42 2.49 to 6.24 
XL HDL triglycerides (%) 363 1.27 0.65 to 1.90      
Medium HDL triglycerides 368 1.21 0.66 to 1.76      
VLDL cholesterol 368 1.42 0.84 to 2.00 465 3.87 2.05 to 5.68 
RemNAt cholesterol      465 3.64 1.78 to 5.50 
LDL triglycerides       465 3.90 2.09 to 5.71 
Diacylglycerol 368 1.26 0.65 to 1.87      
Apolipoprotein B 368 1.17 0.58 to 1.76 465 3.96 2.13 to 5.78 
Total fatty acids      464 3.60 1.81 to 5.38 
MUFA; 16:1, 18:1 368 1.36 0.76 to 1.95 464 4.22 2.39 to 6.06 
Saturated fatty acids      464 3.95 2.05 to 5.85 
Citrate      465 -4.13 -6.10 to -2.16 
Glycoprotein acetyls 368 1.83 1.23 to 2.43 465 5.35 3.45 to 7.25 
Women         
Small HDL concentration 365 2.03 1.23 to 2.83    
Small HDL phospholipids 365 1.98 1.18 to 2.78    
Small HDL total lipids 365 1.96 1.16 to 2.76    
XXL VLDL phospholipids (%) 365 1.88 1.00 to 2.76    
Diacylglycerol 365 1.55 0.80 to 2.29    
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Figure 1. Cross sectional associations between BMI and systemic metabolites at age 60-64. 
The outer circle shows predicted SD change in metabolite levels for every kg/m2 increase in BMI in OLS analysis. 
The middle circle shows ‘Manhattan plot’ with green dots indicating significant p-values after Bonferroni adjustment. 
Variable importance in projection (VIP) from OPLS analysis is shown in inner circle. 
Metabolites identified by the two analyses were indicated with dark blue points. 
See Supplemental Table S1 for abbreviations and grouping based on metabolic processes. 
All models were adjusted for sex, age at NMR blood collection and NMR blood collection centre.
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Figure 2. Cross sectional associations between WHR and systemic metabolites at age 60-64. The outer circle shows predicted SD
change in metabolite levels for every kg/m2 increase in WHR in OLS analysis. The middle circle shows with green
dots indicating significant p-values after Bonferroni adjustment. Variable importance in projection (VIP) from OPLS analysis is
shown in inner circle. Metabolites identified by the two analyses were indicated with dark blue points. See Supplemental Table 1 for
abbreviations and grouping based on metabolic processes. All models were adjusted for sex, age at NMR blood collection and
NMR blood collection centre.
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